达格列净治疗糖尿病慢性并发症的研究进展

doi:10.19739/j.cnki.issn1001-9510.2020.01.017

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (930 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Sodium-glucose cotransporter 2 (SGLT-2) is a key protein molecule involved in glucose reabsorption in the renal tubules, while SGLT-2 expressed in diabetic patients is higher than that in normal people. Therefore, SGLT-2 is a treatment for diabetes and concurrency in recent years. The new target of the disease, its unique mechanism of action has become another innovative study in the field of diabetes. The SGLT-2 inhibitor (SGLT-2i) developed for this target is a non-insulin-dependent new oral hypoglycemic drug that can reduce the reabsorption of glucose by the kidneys and increase the excretion of urine sugar to reduce the effect of blood sugar. Among them, dapagliflozin is a highly active and highly selective SGLT-2i. This article focuses on the research progress of dapagliflozin in improving diabetes and its chronic complications.

Key words： sodium-glucose cotransporter 2 dapagliflozin chronic complications of diabetes

Received: 12 June 2019

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DING Hualin
	YU Suguo

Cite this article:

DING Hualin,YU Suguo. The research progress of daglicaten on chronic complications of diabetes[J]. 滨州医学院学报, 2020, 43(1): 62-64.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2020.01.017 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2020/V43/I1/62

[1] WHALEN K, MILLER S, ONGE E S. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes[J]. Clin Ther, 2015, 37(6): 1150-1166.
[2] SCHEEN A J, PAQUOT N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence[J]. Diabetes Metab, 2014, 40(Suppl 1): S4-S11.
[3] ABASSI Z, LEOR J, LANDA N, et al. Os 05-04 Empagliflozin exerts cardio- and Nephro-protective effects in CohenROSENTHAL diabetic hypertensive rats [J]. J Hypertens, 2016, 34(Suppl ):e58-59.
[4] BOLINDER J, LJUNGGREN O, JOHANSSON L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Diabetes Obes Metab, 2014, 16(2): 159-169.[5] HSU P F, SUNG S H, CHENG H M, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study[J]. Diabetes Care, 2013, 36(4): 894-900.
[6] TANAKA A, MUROHARA T, TAGUCHI I, et al. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study[J]. Cardiovasc Diabetol, 2016, 15(1): 133.
[7] TERAMI N, OKAWA D, TACHIBANA H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, a melio-rates glucose homeostasis and diabetic neph ropathy in db/db mice[J]. PLos One,2014,9(6):e100777.
[8] THOMAS M C. Renal effects of dapagliflozin in patients with type 2 diabetes[J]. Ther Adv Endocrinol Metab, 2014, 5(3): 53-61.
[9] KOHAN D E, FIORETTO P, TANG W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control[J]. Kidney Int, 2014, 85(4): 962-971.
[10] BAKER W L, SMYTH L R, RICHE D M, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis [J]. J Am Soc Hypertens, 2014, 8(4): 262-275.
[11] BJORNSTAD P, LANASPA M A, ISHIMOTO T, et al. Fructose and uric acid in diabetic nephropathy[J]. Diabetologia, 2015, 58(9): 1993-2002.
[12]程晨,周玲,毛红,等.25-羟基维生素D水平与2型糖尿病视网膜病变严重程度的相关性[J].中国生化药物杂志, 2016,36(4):54-57.
[13] GRUNWALD J E, RIVA C E, BAINE J, et al. Total retinal volumetric blood flow rate in diabetic patients with poor glycemic control [J]. Invest Ophthalmol Vis Sci, 1992, 33(2): 356-363.
[14] OTT C, JUMAR A, STRIEPE K, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation [J].Cardiovasc Diabetol, 2017,16(1): 26.
[15] DIXIT S, MAIYA A, SHASTRY B. Effect of aerobic exercise on quality of life in population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, randomized controlled trial [J]. Qual Life Res, 2014, 23(5): 1629-1640.